STAT+: FDA scolds company that raised red flags over impurities in many widely used medicines
Two years after an independent laboratory began pushing the U.S. Food and Drug Administration to…
Category: Pharma
STAT+: Pharmalittle: Zantac lawsuits tossed over inadequate scientific evidence; Lilly tightens access to diabetes drug used for weight loss
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Eli Lilly tightens access to diabetes drug, frustrating some people with obesity
Touted by celebrities, raved about by TikTok users and advertised by med spas, a new…
STAT+: Zantac lawsuits are tossed out as judge lambasts lack of evidence showing links to cancer
Several big drugmakers — Sanofi, GSK, Pfizer and Boehringer Ingelheim — will not have to…
STAT+: The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $805 million in 2021
During 2021, drugmakers substantially raised prices on seven widely used medicines without any new clinical…
STAT+: France’s drug regulator is under investigation for its handling of a thyroid drug
France’s drug regulator is being investigated for issuing misleading information in connection with a thyroid…
.jpg)
STAT+: U.S. delays backing for patent waivers on Covid-19 therapies and diagnostics
The U.S. government will not support extending a Dec. 17 deadline for waiving intellectual property…
.jpg)
STAT+: Pharmalittle: FDA fast tracks OTC version of Narcan; Express Scripts to keep Humira on its formulary but add biosimilars
Hello, everyone, and how are you today? A steely gray sky is hovering this morning…
STAT+: A year after petition, NIH reviews request to lower cancer drug’s cost by sidestepping patents
One year after being asked to widen access to a pricey cancer treatment by using…
STAT+: Pharmalittle: J&J drops out of bidding for Horizon; FDA takes a harder line on fast-track approvals
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep care
In the fight to command the growing market for telehealth, Thirty Madison is staking out…
STAT+: Pharmalittle: Private equity moving to buy clinical trials firms; data provider limits media access to drug prices
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Gilead wins a key battle with the CDC over patents for its Truvada HIV pill
Gilead Sciences won a key round in its battle with the U.S. government over allegations…
STAT+: Pharmalittle: Roche Alzheimer’s drug didn’t clear enough amyloid; startup to seek approval of nasal swab version of naloxone
Good morning, Jason Mast here filling in for Ed. There are many types of coffee…
STAT+: Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
At a time when many Americans are clamoring for more transparency into prescription drug pricing,…
STAT+: Pharmalittle: Detailed data on Alzheimer’s drug hold up to scrutiny; Horizon in takeover talks with three pharma giants
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues
In the spring of 1981, a geneticist from Indianapolis and a neurologist from Chicago got…
STAT+: Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug
Hello, everyone, and how are you today? Gray skies are hovering over the Pharmalot campus…
STAT+: ‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period
A hotly contested provision of a federal law designed to speed copycat drugs to market…
STAT+: Pharmalittle: Second clinical trial death may be linked to Eisai-Biogen Alzheimer’s drug; pharma presses the U.K. over ‘out of control’ levy
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Former Merck CEO: Democracy and the drug industry are both in danger
Ken Frazier, the former chief executive of Merck, has been the preeminent pharmaceutical CEO of…
Q&A: Siddhartha Mukherjee on the rapid pace of cancer research and ‘luminous’ life of cells
The first cells Siddhartha Mukherjee ever saw were T cells, pulled from a mouse spleen…
STAT+: Pharmalittle: FDA approves first gene therapy for hemophilia B; pharma’s reputation slips in U.S.
Happy Thanksgiving Eve from STAT reporter Andrew Joseph, filling in for the day. A note…
STAT+: Pharmalittle: GSK pulls a key blood-cancer drug off the market; Teva picks a new CEO
Good morning, everyone. Damian Garde here filling in for Ed Silverman in the waning days…
STAT+: Pharmalittle: Type 1 diabetes drug is priced at $194,000; abortion opponents sue FDA over abortion pill approval
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases
Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs…
Watch: This small-town pharmacy may be a model for more affordable drugs
STAUNTON, Va. — Honest Rx operates like any other pharmacy in the United States —…
Pfizer CEO says Covid vaccine will remain ‘free for all Americans,’ overlooking indirect costs
BOSTON — As Pfizer prepares to hike the price of its Covid-19 vaccines, the company’s…
STAT+: Sales of antibiotics for food-producing animals dropped by nearly half in Europe over the past decade
Amid ongoing concerns over the use of medically important antibiotics given to food-producing livestock and…
STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Big PBM keeps AbbVie’s Humira on formulary; Lilly CEO says fake tweet means there’s more to do on insulin costs
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Lilly CEO concedes Twitter flap over insulin costs shows there’s ‘more work to do’
After a tweet from a fake corporate account last week claimed Eli Lilly would give…
Opinion: The conundrum of biopharma investing: low rewards and high risks — but a big social benefit
Over the last decade, investors in biotech and pharmaceutical companies have been taking risks that…
STAT+: Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Walmart agrees to pay $3.1 billion in latest settlement stemming from the opioid crisis
In the latest fallout from the opioid crisis that swept the U.S., Walmart agreed to…
STAT+: Pharmalittle: Walmart to pay $3.1 billion to settle opioid claims; Indian Covid vaccine underwent troubling approval process
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in Spain have fined a drugmaker $10.6 million for years of “excessive” price…
STAT+: More drugmakers are expanding access in poorer countries, but progress continues to lag overall
For the first time, many of the world’s largest pharmaceutical companies are taking concrete steps…
‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process
As the Covid-19 pandemic spread across the world two years ago, one of India’s leading…
STAT+: Pharmalittle: Roche Alzheimer’s drug fails in two studies; Indivior bets on addiction market with deal to buy Opiant
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Lilly says fake Twitter account offered free insulin; AstraZeneca drops plans for Covid shot in the U.S.
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Viatris executive is charged with insider trading scheme involving a friend and former colleague
A high-ranking Viatris executive was charged with insider trading for tipping a friend and former…
STAT+: Pharmalittle: Biogen hires Viehbacher as its CEO; new dengue vaccine rolled out amid safety concerns
Top of the morning to you, and a fine one it is. Crystal clear blue…
STAT+: Pharmalittle: ADC backs off accelerated approval after FDA demands confirmatory trial; explaining the Supreme Court’s split on drug-patent cases
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
In a surprising move, the U.S. Supreme Court rejected a bid by a Bristol Myers…
STAT+: Pharmalittle: Biogen mulls new options in its CEO hunt; NIH starts contacting universities about overdue trial results
Rise and shine, everyone, another busy day is on the way. This is especially true…
STAT+: After years of lax oversight, the NIH is starting to contact institutions about unreported clinical trial results
In recent weeks, the U.S. National Institutes of Health has begun emailing academic institutions that…
STAT+: Amid concerns over U.S. democracy, pharma helped finance committees that support election deniers
As Americans head to the polls, some candidates continue to deny the results of the…
STAT+: Pharmalittle: Some Lilly workers want transfers due to Indiana abortion law; GSK cancer drug flops in late-stage study
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Health and science are on the ballot this election. Here’s what we’re watching
WASHINGTON — The midterm elections this year are centered on weighty topics: the economy looms…